DHVI Receives Contract Renewal for HIV/AIDS Quality Control
DURHAM, N.C. – The Duke Human Vaccine Institute received a contract renewal to again provide quality control for research laboratories across the globe involved in federally-funded HIV/AIDS studies.
If the government exercises all of its options under the contract, the seven-year contract renewal will provide a total of $13.9 million in funding from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.
Thomas Denny, MSc., M.Phil., chief operating officer of DHVI, will again serve as the principal investigator of the Immunology Quality Assessment Program. Denny has led the project since 1999.
The contract provides the infrastructure for the DHVI group to conduct quality control oversight of laboratories throughout the world that engage in NIH-funded research in HIV/AIDS. The team currently works with nearly 70 North American laboratories and 92 international laboratories spread across 18 countries. Monitoring laboratory performance assesses whether laboratory tests are uniformly conducted so that highly sensitive data can be compared regardless of where it is generated.
“We are pleased to receive funding once again for this important oversight role,” Denny said. “We have a great team and a great facility at the Duke Human Vaccine Institute, and we were able to show we have a long term track record of performing this role well.”